Mostrar el registro sencillo del ítem

dc.contributor.authorNaldaiz-Gastesi, Neia
dc.contributor.authorGoicoechea, María
dc.contributor.authorAragón, Isabel Maria 
dc.contributor.authorPérez-López, Virginia
dc.contributor.authorFuertes-Alvarez, Sandra
dc.contributor.authorHerrera-Imbroda, Bernardo
dc.contributor.authorLópez de Munain, Adolfo
dc.contributor.authorde Luna-Diaz, Resi
dc.contributor.authorBaptista, Pedro M
dc.contributor.authorFernández, M Alejandro
dc.contributor.authorLara, María Fernanda
dc.contributor.authorIzeta, Ander
dc.date.accessioned2019-07-03T11:43:57Z
dc.date.available2019-07-03T11:43:57Z
dc.date.issued2019-03-05
dc.identifier.citationSci Rep. 2019;9(1):3454.es_ES
dc.identifier.issn2045-2322es_ES
dc.identifier.otherhttp://hdl.handle.net/10668/13662
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7845
dc.description.abstractHuman myogenic precursor cells have been isolated and expanded from a number of skeletal muscles, but alternative donor biopsy sites must be sought after in diseases where muscle damage is widespread. Biopsy sites must be relatively accessible, and the biopsied muscle dispensable. Here, we aimed to histologically characterize the cremaster muscle with regard number of satellite cells and regenerative fibres, and to isolate and characterize human cremaster muscle-derived stem/precursor cells in adult male donors with the objective of characterizing this muscle as a novel source of myogenic precursor cells. Cremaster muscle biopsies (or adjacent non-muscle tissue for negative controls; N = 19) were taken from male patients undergoing routine surgery for urogenital pathology. Myosphere cultures were derived and tested for their in vitro and in vivo myogenic differentiation and muscle regeneration capacities. Cremaster-derived myogenic precursor cells were maintained by myosphere culture and efficiently differentiated to myotubes in adhesion culture. Upon transplantation to an immunocompromised mouse model of cardiotoxin-induced acute muscle damage, human cremaster-derived myogenic precursor cells survived to the transplants and contributed to muscle regeneration. These precursors are a good candidate for cell therapy approaches of skeletal muscle. Due to their location and developmental origin, we propose that they might be best suited for regeneration of the rhabdosphincter in patients undergoing stress urinary incontinence after radical prostatectomy.es_ES
dc.description.sponsorshipWe thank patients and medical personnel for their generous involvement in the study. We also acknowledge the help of Biodonostia Animal and Experimental Operations Facility. This work was supported by grants from Ministerio de Economía y Competitividad (RTC-2015-3750-1) and Instituto de Salud Carlos III (PI13/02172, PI16/01430) to A.I., co-funded by the European Union (ERDF/ESF, ‘Investing in your future’). N.N.-G. received a studentship from the Department of Education, University and Research of the Basque Government (PRE2013-1-1168). A.L.M. was funded by grants from FIS (PI17/01841 and PI14/00436), CIBERNED and the Basque Government (2015/11038, RIS3 2017222021 and BIO16/ER/022). M.F.L.-C. was supported by the Servicio Andaluz de Salud from the Consejería de Salud de la Junta de Andalucía, grant PI 0222-2014, co-funded by the European Union (ERDF/ESF). I.M.A was funded by grants from Ministerio de Economia y Competitividad (PEJ-2014-P-01215 and FJCI-2016-28121).es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectHUMAN SKELETAL-MUSCLEes_ES
dc.subjectTHERAPIESes_ES
dc.subjectSTEM-CELLSes_ES
dc.subjectSATELLITE CELLSes_ES
dc.subjectADIPOGENIC PROGENITORS;es_ES
dc.subjectIN-VITRO;es_ES
dc.subjectURINARY-INCONTINENCEes_ES
dc.subjectREGENERATIONes_ES
dc.subjectTESTICULAR DESCENTes_ES
dc.subjectTRANSPLANTATIONes_ES
dc.titleIsolation and characterization of myogenic precursor cells from human cremaster musclees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30837559es_ES
dc.format.volume9es_ES
dc.format.number1es_ES
dc.format.page3454es_ES
dc.identifier.doi10.1038/s41598-019-40042-6es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderBasque Government (España) 
dc.contributor.funderRegional Government of Andalusia (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/ 10.1038/s41598-019-40042-6.es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer de Próstataes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RTC-2015-3750-1es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PEJ-2014-P-01215es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FJCI-2016-28121es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/02172es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01430es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PRE2013-1-1168es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/01841es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/00436es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2015/11038es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RIS3 2017222021es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO16/ER/022es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI 0222-2014es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional